1007215-41-9Relevant articles and documents
Modification of a dihydropyrrolopyrimidine phosphoinositide 3-kinase (PI3K) inhibitor to improve oral bioavailability
Kawada, Hatsuo,Ebiike, Hirosato,Tsukazaki, Masao,Yamamoto, Shun,Koyama, Kohei,Nakamura, Mitsuaki,Morikami, Kenji,Yoshinari, Kiyoshi,Yoshida, Miyuki,Ogawa, Kotaro,Shinma, Nobuo,Tsukuda, Takuo,Ohwada, Jun
, p. 7650 - 7660 (2015/12/18)
Phosphoinositide 3-kinase (PI3K) is activated in various human cancer cells and well known as a cancer therapy target. We previously reported a dihydropyrrolopyrimidine derivative as a highly potent PI3K inhibitor that has strong tumor growth inhibition in a xenograft model. In this report, we describe further optimization to improve its bioavailability.